Bio-Rad launches mixed-mode chromatography resin for therapeutic protein purification
Bio-Rad Laboratories has introduced a new mixed-mode chromatography resin designed for biomolecule purification across multiple scales. The Nuvia wPrime 2A Media combines weak anion exchange with hydrophobic interaction chromatography, offering potential advantages for both research and industrial-scale therapeutic protein production
Technical specifications
The newly launched resin incorporates Bio-Rad’s established Nuvia bead technology, utilising a polyacrylamide base bead structure. This design provides consistent dynamic binding capacity across varying flow rates whilst minimising non-specific binding through the hydrophilic nature of the polymer matrix. The mechanical and chemical stability of the beads facilitates reliable column packing and operational flexibility.
A key feature of the Nuvia wPrime 2A Media is its pH-modulated functional ligand, which enables fine-tuned separation of challenging
biomolecules from process-related impurities. The resin has demonstrated efficacy in removing host cell proteins, molecular weight variants, and DNA contaminants during the purification of both conventional and bispecific antibodies, as well as adeno-associated viral vectors.
Scalability and manufacturing considerations
The development process involved collabo-ration with industrial partners to ensure the resin’s suitability for manufacturing-scale applications. The product supports a seamless transition from laboratory-scale purification through to pilot and full-scale bioproduction, maintaining consistent performance characteristics across different operational scales.
Diab Elmashni, Director of Process Chromatography Business at Bio-Rad Laboratories, highlighted the company’s focus on meeting diverse customer requirements: “Bio-Rad is committed to developing innovative chromatography resins for a wide variety of customer needs, and to advancing the efforts of researchers and therapy manufacturers alike in saving lives.”
Elmashni also emphasised the strategic importance of the product launch, noting: “As a leader in multimodal chromatography technology, Bio-Rad’s Nuvia and CHT Ceramic Hydroxyapatite families of resins and media are integral to pharmaceutical development and industrial-scale purification for many customers worldwide. This new resin is unique to the market and addresses customer requests for a scalable, weak anion exchange and hydrophobic interaction mixed-mode resin.”
• For more information about Nuvia wPrime 2A Media, visit: www.bio-rad.com/wPrime2A
Digital issue:
Please click here for more information
